Chronic hepatitis C virus (HCV) disease burden and cost in the United States
Hepatology2012Vol. 57(6), pp. 2164–2170
Citations Over TimeTop 1% of 2012 papers
Homie Razavi, Antoine C. ElKhoury, Elamin H. Elbasha, Chris Estes, K. Pasini, Thierry Poynard, Ritesh Kumar
Abstract
This analysis demonstrates that US HCV prevalence is in decline due to a lower incidence of infections. However, the prevalence of advanced liver disease will continue to increase as well as the corresponding healthcare costs. Lifetime healthcare costs for an HCV-infected person are significantly higher than for noninfected persons. In addition, it is possible to substantially reduce HCV infection through active management. (HEPATOLOGY 2013;57:2164-2170).
Related Papers
- → Hepatitis C Virus-Associated Primary Hepatocellular Carcinoma in Non-cirrhotic Patients(2012)19 cited
- → Hepatocellular carcinoma after sustained virologic response in hepatitis C patients without cirrhosis on a pretreatment liver biopsy(2009)15 cited
- → Hepatitis C virus 1b is the dominant genotype in HCV-related carcinogenesis: A case-control study(1996)50 cited
- → Comparison of serum and liver hepatitis C virus quasispecies in HCV-related hepatocellular carcinoma(1998)21 cited
- → Does HCV antiviral therapy decrease the risk of hepatocellular carcinoma?(2008)1 cited